Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathias Jachs

Showing results (1-10 of 118) with videos related to

Pageof 12
Sort By:
Clinical and Molecular Hepatology|March 19, 2025
Predicting decompensation risk in compensated HBV cirrhosis: Eternal sunshine for a spotless mind?Mathias Jachs, Mattias Mandorfer
Clinics in Liver Disease|April 11, 2021
Prevention of Variceal Bleeding and Rebleeding by Nonselective Beta-Blockers: A Tailored ApproachMathias Jachs, Thomas Reiberger
Clinical and Molecular Hepatology|April 16, 2025
Reply to authors' reply: "Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis"Mathias Jachs, Mattias Mandorfer
Hepatology (Baltimore, Md.)|September 17, 2022
It's not all about the virus-On the importance of modifiable lifestyle factors in the development of hepatocellular carcinoma in chronic hepatitis BMathias Jachs, Hans L Tillmann
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 6, 2021
ReplyMattias Mandorfer, Thomas Reiberger, Mathias Jachs
Alimentary Pharmacology & Therapeutics|January 15, 2023
Letter: chronic HDV infection-is ignorance bliss? Authors' replyMathias Jachs, Thomas Reiberger, Peter Ferenci
Alimentary Pharmacology & Therapeutics|May 26, 2026
Editorial: Bile Acids Under Bulevirtide-A Pharmacodynamic Signature, Not a Prognostic Biomarker. Authors' ReplyMarlene Hintersteininger, Thomas Reiberger, Mathias Jachs
Alimentary Pharmacology & Therapeutics|August 8, 2022
Editorial: pegylated interferon combined with bulevirtide for chronic hepatitis delta-new life for an old timer? Authors' replyMathias Jachs, Thomas Reiberger, Peter Ferenci
Clinical and Molecular Hepatology|November 23, 2022
Non-invasive tests-based risk stratification: Baveno VII and beyondGeorg Semmler, Mathias Jachs, Mattias Mandorfer
Cells|November 26, 2022
Treatment of Chronic Hepatitis D with Bulevirtide-A Fight against Two Foes-An UpdatePeter Ferenci, Thomas Reiberger, Mathias Jachs
Pageof 12

Showing results (1-10 of 118) with videos related to

Sort By:
Pageof 12
Clinical and Molecular Hepatology|March 19, 2025
Predicting decompensation risk in compensated HBV cirrhosis: Eternal sunshine for a spotless mind?Mathias Jachs, Mattias Mandorfer
Clinics in Liver Disease|April 11, 2021
Prevention of Variceal Bleeding and Rebleeding by Nonselective Beta-Blockers: A Tailored ApproachMathias Jachs, Thomas Reiberger
Clinical and Molecular Hepatology|April 16, 2025
Reply to authors' reply: "Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis"Mathias Jachs, Mattias Mandorfer
Hepatology (Baltimore, Md.)|September 17, 2022
It's not all about the virus-On the importance of modifiable lifestyle factors in the development of hepatocellular carcinoma in chronic hepatitis BMathias Jachs, Hans L Tillmann
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 6, 2021
ReplyMattias Mandorfer, Thomas Reiberger, Mathias Jachs
Alimentary Pharmacology & Therapeutics|January 15, 2023
Letter: chronic HDV infection-is ignorance bliss? Authors' replyMathias Jachs, Thomas Reiberger, Peter Ferenci
Alimentary Pharmacology & Therapeutics|May 26, 2026
Editorial: Bile Acids Under Bulevirtide-A Pharmacodynamic Signature, Not a Prognostic Biomarker. Authors' ReplyMarlene Hintersteininger, Thomas Reiberger, Mathias Jachs
Alimentary Pharmacology & Therapeutics|August 8, 2022
Editorial: pegylated interferon combined with bulevirtide for chronic hepatitis delta-new life for an old timer? Authors' replyMathias Jachs, Thomas Reiberger, Peter Ferenci
Clinical and Molecular Hepatology|November 23, 2022
Non-invasive tests-based risk stratification: Baveno VII and beyondGeorg Semmler, Mathias Jachs, Mattias Mandorfer
Cells|November 26, 2022
Treatment of Chronic Hepatitis D with Bulevirtide-A Fight against Two Foes-An UpdatePeter Ferenci, Thomas Reiberger, Mathias Jachs
Pageof 12